SPY330.06+1.27 0.39%
DIA268.41+1.69 0.63%
IXIC10,941.17+38.37 0.35%

H.C. Wainwright Maintains Buy on Akebia Therapeutics, Lowers Price Target to $16

H.C. Wainwright maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $17 to $16.

Benzinga · -

H.C. Wainwright maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $17 to $16.